L-lysine as adjunctive treatment in patients with schizophrenia: a single-blinded, randomized, cross-over pilot study
2011 · BMC Medicine · 27 citations
https://doi.org/10.1186/1741-7015-9-40
D
Daniel Klamer
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
44
Papers
973
Citations
22
h-index
29
i10-index
Daniel Klamer is an academic researcher from IDEX Corporation (United States). The author has contributed to research in topics: Neuroscience and Neuropharmacology Research & Receptor Mechanisms and Signaling & Neurotransmitter Receptor Influence on Behavior. The author has an h-index of 22, co-authored 38 publications.
Papers by this author
worksEffects of the sigma-1 receptor agonist blarcamesine in a murine model of fragile X syndrome: neurobehavioral phenotypes and receptor occupancy
2021 · Scientific Reports · 19 citations
https://doi.org/10.1038/s41598-021-94079-7
Brain cell signaling abnormalities are detected in blood in a murine model of Fragile X syndrome and corrected by Sigma‐1 receptor agonist Blarcamesine
2022 · American Journal of Medical Genetics Part A · 3 citations
https://doi.org/10.1002/ajmg.a.62853
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat